Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

Name: Αlpha¹ Rigor Record — Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
Item: Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
Rating: 100
Author: Αlpha¹

Cascone T, Bonanno L, Guisier F, Insa A, Liberman M, Bylicki O, Livi L, Egenod T, Corre R, Kim DW, Garcia Campelo MR, Provencio Pulla M, Shim BY, Metro G, Bennouna J, Bielska AA, Yohannes AR, He Y, Dowson A, Kar G, McGrath L, Kumar R, Grenga I, Spicer J, Forde PM

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 2 high issues for “Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
LinksDead data/code link−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.

Problems surfaced4 types

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Dead data/code linksRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase II platform trial. The paper demonstrates strong scientific premise, adequate study design, thorough ethical approvals, and transparent reporting. Minor issues include a missing explicit reporting guideline statement, a dead link in the data availability, and a few copyedit typos.

Both reviewers agreed on the study type (interventional) and on all dimension statuses. Minor divergences in checklist sub-ratings (e.g., power analysis, reporting guideline) were reconciled by considering the paper's explicit statements. The statistics verification component checked 0 tests (none recomputable), so no claims of statistical correctness are made beyond what was reported.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Reporting

Eight Dimensions8 pass

The introduction cites multiple pivotal trials and the NeoCOAST study, acknowledging the unmet need with pCR rates and EFS. The rationale for combining durvalumab with oleclumab, monalizumab, and Dato-DXd is logically linked to their mechanisms and prior evidence. Limitations of prior research are implicitly addressed by the platform design and the focus on novel agents.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior phase III trials (AEGEAN, KEYNOTE-671, CheckMate 77T, CheckMate 816) and the NeoCOAST study, and clearly rationalizes the need for novel combinations.

Evidence

direct quote[Introduction, paragraph 1]

“In the phase III AEGEAN study, perioperative durvalumab plus neoadjuvant chemotherapy led to significantly higher rates of pCR (17.2% versus 4.3%; P < 0.001) and significantly longer event-free survival (EFS; hazard ratio 0.68; 95% confidence interval (CI), 0.53–0.88) compared with neoadjuvant chemotherapy alone”